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Orthopedic Surgeon’s Awareness Can Improve Osteoporosis 
Treatment Following Hip Fracture: A Prospective Cohort Study 
Through retrospective Jeju-cohort study at 2005, we found low rates of detection of 
osteoporosis (20.1%) and medication for osteoporosis (15.5%) in those who experienced 
hip fracture. This study was to determine the orthopedic surgeons’ awareness could 
increase the osteoporosis treatment rate after a hip fracture and the patient barriers to 
osteoporosis management. We prospectively followed 208 patients older than 50 yr who 
were enrolled for hip fractures during 2007 in Jeju-cohort. Thirty four fractures in men and 
174 in women were treated at the eight hospitals. During the study period, orthopedic 
surgeons who worked at these hospitals attended two education sessions and were 
provided with posters and brochures. Patients were interviewed 6 months after discharge 
using an evaluation questionnaire regarding their perceptions of barriers to osteoporosis 
treatment. The patients were followed for a minimum of one year. Ninety-four patients 
(45.2%) underwent detection of osteoporosis by dual energy x-ray absorptiometry and 67 
(32.2%) were prescribed medication for osteoporosis at the time of discharge. According 
to the questionnaire, the most common barrier to treatment for osteoporosis after a hip 
fracture was patients reluctance. The detection and medication rate for osteoporosis after 
hip fracture increased twofold after orthopedic surgeons had attended the intervention 
program. Nevertheless, the osteoporosis treatment rate remains inadequate. 
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ORIGINAL ARTICLE
Musculoskeletal Disorders
INTRODUCTION
Osteoporosis is a common skeletal disease in elderly popula-
tion, and osteoporosis-induced fractures are serious problems 
that pose considerable social and economic burdens in devel-
oped and developing countries (1-4). Osteoporosis is associat-
ed with low-energy fragility fractures which occur commonly in 
the hip, wrist, or vertebra. Of these, hip fractures are the most 
serious and have high rates of mortality and morbidity (3, 4). 
The history of hip fracture indicates a 5% risk of another hip frac-
ture within a year, a 17 to 21% risk of any fracture within 16 to 21 
months, and a 29% risk of another hip fracture in the following 
20 yr (5, 6).
  However, treatment for osteoporosis in patients older than  
50 yr is not always instituted because of the asymptomatic and 
slowly progressive nature of the disease. Many patients will not 
be evaluated and/or treated until it is recognized in conjunc-
tion with a fragility fracture (7-9). However, even after hip frac-
ture the rate of diagnosis and treatment of osteoporosis is still 
low at 5% to 25% (10-13).  
  Several studies have shown that osteoporosis treatment after 
a hip or any fragility fracture reduces the risks of subsequent frac-
tures and mortality (14-16). It is known that a perioperative inter-
vention program increased the percentage of patients in whom 
osteoporosis was addressed following a hip fracture. The role of 
orthopedic surgeons has been highlighted as part of the solu-
tion to recurrent fractures (17). Nonetheless, some orthopedic 
surgeons believe osteoporosis management after a hip fracture 
is not their responsibility (18-20). However, recent studies showed 
that active participation of orthopedic surgeons in the manage-
ment of osteoporosis after a hip fracture improves treatment 
rates (21-23).
  In 2007, we reported (24) a retrospective observational study 
of 174 patients with age of 50 yr or older who were admitted for 
a hip fracture between January 1 and December 31, 2005 from 
eight hospitals. One hundred seventy-four patients were en-
rolled and followed up for one year. Of these patients, only 35 
(20.1%) underwent detection of osteoporosis by dual energy x-
ray absorptiometry (DXA) and 27 (15.5%) received medication 
for osteoporosis at the time of discharge.
  We performed a before and after study of educational pro-
gram for orthopedic surgeons to determine whether this pro-
gram is warranted or not. We wished to determine 1) whether 
an education program directed at orthopedic surgeons could 
increase the osteoporosis treatment rate after a hip fracture, 2) 
whether the difference of mortality between osteoporosis man-Kim S-R, et al.  •  Orthopedic Surgeon’s Awareness on Osteoporosis
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Table 1. Patient’s demographic data 
Parameters  Findings
Number of patients  208 
Man:Woman  34 (16.3%):174 (83.7%)
Age (yr) (mean ± SD) 79.1 ± 9.1 (range, 52-99)
Mean period of hospital follow-up (months) 8.8 (range, 1-24)
Diagnosis of hip fracture
   Neck 
   Intertrochanter
 
 107 (51.4%)
 101 (48.6%)
Management
   Conservative
   Operation
 
 15 (7.2%)
 193 (92.8%)
Coexisting medical disease
   Hypertension and heart problem
   Diabetes mellitus
   Depression and dementia
   Previous stroke
   Pneumonia and COPD
   Cancer
   Others
 
   84 (40.4%) 
   35 (16.8%)
   32 (15.4%)
27 (13%)
 18 (8.7%)
   6 (2.9%)
 18 (8.7%)
DXA
   Prior to hip fracture
   After hip fracture
      Osteoporosis (-2.5 ≥ T-score)
      Osteopenia (-1 > T-score > 2.5)
 
   7 (3.4%)
   94 (45.2%)
   93 (44.7%)
   1 (0.5%)
Bisphosphonate medication 
   Prior to hip fracture
   After hip fracture
 
2 (1%)
   67 (32.2%)
Duration of bisphosphonate medication
   < 6 months
   ≥ 6 months
 
25 (12%)
   42 (20.2%)
Mean period of medication (months) 9.5 (range, 1-24)
SD, standard deviation; COPD, chronic obstructive pulmonary disease; DXA, dual en-
ergy x-ray absorptiometry.
agement group and none management group, and 3) the patient 
barriers to osteoporosis management after a hip fracture.
MATERIALS AND METHODS
Participants in the study were drawn from a cohort that has been 
monitored from 2002 to 2007 for whom the incidences of hip 
fractures and mortality and morbidity rates were determined 
after hip fracture. This large cohort was recruited on Jeju Island, 
the largest island in Korea, which is located southwest of the 
Korean peninsula. In 2007, its population was 559,258. There 
are 8 hospitals (one university hospital and seven general hos-
pitals) on the island with an orthopedic department and emer-
gency admission facilities. Jeju island is geographically isolated 
from Korean peninsula and patients with hip fracture usually 
require hospitalization, which makes ascertainment of patient 
follow-up easier and much reliable than other areas. This pro-
spective cohort study was performed using the same patient 
database at the eight hospitals as used in our 2007 study and the 
same inclusion and exclusion criteria (24). Two hundred twenty 
seven patients older than 50 yr with hip fractures who were ad-
mitted to one of the 8 hospitals between January 1, and Decem-
ber 31, 2007 were candidates for the study. Nineteen patients 
were excluded for the following reasons: 14 for a high-energy 
injury resulting from a traffic accident or fall from height, 3 be-
cause they were nonresidents, and 2 because they had a patho-
logic fracture. A total of 208 patients with hip fractures (107 fem-
oral neck fractures [51.4%] and 101 intertrochanteric fractures 
[48.6%] [34 men and 174 women]) was enrolled in this interven-
tion study. The mean age of the patients at the time of diagnosis 
was 79.1 yr (men, 72.2 yr, range, 52-92 yr; women, 80.5 yr range, 
52-97 yr). The most common coexisting medical conditions at 
admission were hypertension and heart disease, diabetes melli-
tus, depression and mental illness, previous stroke, and lung dis-
ease (Table 1). Of the 208 patients, 193 underwent surgery, but 
15 did not. Five patents underwent nonoperative treatment for 
a nondisplaced fracture and 10 patients, confirmed to be high 
risks for surgery, were discharged without further treatment. 
Thirty-eight of the 208 patients died during the follow-up peri-
od, 8 who lived alone could not respond during the interview 
owing to dementia or deafness, and 25 could not be interviewed 
owing to change in contact information. Seventy-nine patients 
(38%) were followed for less than 6 months and 53 patients (25.5 
%) were followed for less than 12 months during the 1-yr follow-
up period. Of the 38 patients who died, 22 (10.6%) succumbed 
during the first 6 months of the follow-up, 30 (14.4%) died by 12 
months, and 38 (18.3%) had died by the final follow-up of 19 
months. 
  We calculated the required study sample size using the 2005 
data, in which the initiation rate of osteoporosis treatment was 
15.5%. Based on a power of 80%, significance level of 5%, and 
an estimated increasing rate of osteoporosis treatment of 10% 
in the patients who were diagnosed with hip fractures, the in-
clusion of 149 patients was estimated as an optimal sample size. 
As we expected a drop-out rate of 20% during follow-up owing 
to the high mortality rate after hip fracture, we included 180 pa-
tients in the intervention study.
  Six of 8 hospitals used DXA to determine bone mineral den-
sities. The other 2 hospitals treated fewer than 5 hip fractures per 
year, and referred patients to another hospital for DXA. 
  Twenty-two orthopedic surgeons who worked at the 8 hospi-
tals were provided with 2 education sessions (in January and July 
2007) and educational posters (March) and brochures (October) 
for increasing osteoporosis management. These education ses-
sions involved providing information regarding the association 
between osteoporosis and hip fracture, the efficacy of DXA for 
diagnosis of osteoporosis, the effectiveness of antiosteoporotic 
drugs, and the importance of followup for management of os-
teoporosis and of routine orthopedic follow-up. All orthopedic 
surgeons who treated hip fractures in the cohort completed the 
educational programs. 
  Hospital data evaluations were performed 6 and 12 months 
after discharge from the hospital, and every 6 months thereafter. 
From the medical records we determined diagnosis at admis-Kim S-R, et al.  •  Orthopaedic Surgeon’s Awareness on Osteoporosis
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sion, mechanism of injury, DXA, procedures performed during 
hospitalization, and discharge medications. Regardless of fol-
low-up compliance, patients were asked 6 questions using a ques-
tionnaire format that addressed information provided by clini-
cians regarding osteoporosis, diagnosis of osteoporosis, osteo-
porosis medication, name of antiosteoporotic medication, ac-
tivity after hip fracture, and personal barriers to management of 
osteoporosis. Osteoporosis treatment was defined as medication 
including a selective estrogen receptor modulator, bisphospho-
nate, calcitonin therapy or hormone replacement. Seven of the 
208 patients had a diagnosis of osteoporosis before hip fracture, 
but only 3 of these 7 were taking prescribed osteoporosis medi-
cations at the time of admission. Treatment initiation and dura-
tion were confirmed by reviewing medical records at 6 months 
and 12 months after discharge from hospital. Mortality status of 
the patients was identified from hospital records and/or inter-
views with patients’ families. Also, death certificates at the Sta-
tistics Korea were searched for information for patients lost to 
follow-up. For subgroup analysis, we analyzed demographic 
data between osteoporosis treatment group and nonosteopo-
rosis treatment group. 
  The chi-square test was used to analyze mortality rate of os-
teoporosis management group and none management group, 
rate of osteoporosis detection, and initiation rate of osteoporo-
sis treatment between 2005 cohort and 2007 cohort. SPSS, ver-
sion 15.0 (Chicago, IL, USA), was used for the analysis.
Ethics statement
The design and protocol of this study were approved by the in-
stitutional review board at the Cheju National University Hos-
pital (CNUH-IRB No 2008-19). Patients were informed that their 
medical data might be used in a scientific study and they pro-
vided consent.
RESULTS
In 2007 the rate of osteoporosis detection was greater (P < 0.001) 
than that in 2005 (45% vs 20.1%) and the initiation rate of osteo-
porosis treatment also had increased (32.2% vs 15.1%) (Table 2). 
Among the 22 orthopedic surgeons, who participated in this 
study, the physician’s detection rate and treatment rate increased 
in 15. Ninety-four patients (45.2%) underwent DXA during ad-
mission; hip and spine in 90, hip in 3, and spine in 1. Ninety-
three of these 94 patients (99%) had osteoporosis (T score ≤ -2.5) 
and one had osteopenia (-2.5 < T score < -1. No patient received 
a DXA scan after hospital discharge during the study period. Of 
these 94 patients, 67 (71.3%) were prescribed only oral bisphos-
phonates (risedronate, 30/67 [43.5%], or alendronate, 39/67 
[56.5%]) at the time of discharge. Other antiosteoporotic drugs 
such as, selective estrogen receptor modulator, calcitonin, and 
hormone replacement therapy were not prescribed. Fourteen 
patients received once-a-day bisphosphonate and 53 received 
once-a-week bisphosphonate. The mean duration of time these 
patients were taking osteoporosis medication, was 9.5 months 
(range, 1-24 months), and 25 patients (37.3%) received medica-
tion for less than 6 months.
  At last follow-up, the mortality rate was higher (P = 0.044) in 
the nonmedicated groups (31/141) than in the medicated group 
Table 2. Comparison data of osteoporosis treatment after hip fracture or fragility fracture 
Author Study design Trial subject Intervention Outcomes (control) Outcomes (intervention)
Cranney et al. [26] 
   2008
Prospective RCT PCPs and patients Education BMD scan 26% (36/141)
Osteoporosis Tx 10% (15/145)
BMD scan 53% (64/120)
Osteoporosis Tx 28% (35/125)
Gardner et al. [21] 
   2005
Prospective RCT PCPs and patients Education BMD scan 17% (6/36)
Osteoporosis Tx 17% (6/36)
BMD scan 33% (12/36)
Osteoporosis Tx 28% (10/36)
Majumdar et al. [27] 
   2007
Prospective RCT Physician and patients Education BMD scan 29% (32/110)
Osteoporosis Tx 22% (24/110)
BMD scan 80% (88/111)
Osteoporosis Tx 51% (56/110)
Miki et al. [22] 
   2008
Prospective RCT Orthopedic surgeon and 
patients
Education BMD scan 29% (7/24)
Osteoporosis Tx 29% (7/24)
BMD scan 100% (26/26)
Osteoporosis Tx 58% (15/26)
Streeten et al. [23]
   2006
Prospective design 
and retrospective review
Orthopedic team Osteoporosis 
consultation
Osteoporosis Tx 3.2% (1/31) Osteoporosis Tx 52.8% (28/53)
Current study  Prospective before 
and after study 
Orthopedic surgeon Education BMD scan 20.1% (35/174)
Osteoporosis Tx 15.5% (27/174)
BMD scan 45% (94/208)
Osteoporosis Tx 32.2% (67/208)
RCT, randomized control trial; BMD, bone mineral density; Tx, treatment; PCPs, primary care physician.
Table 3. Subgroup analysis between osteoporosis treatment group and nonosteopo-
rosis treatment group
Treatment group 
(n = 68)
Nontreatment 
group (n = 139)
P value
Gender (man/woman) 5/63 29/111 0.015
Age (mean ± SD) (yr) 78.4 ± 7.45 79.5 ± 9.75 0.384
Diagnosis 
   Neck
   Intertrochanter 
26
42
 
81
59
0.008
Operation 
   Yes
   No
 
65
  3
 
128
12
0.277
Comorbidity
   Hypertension and heart problem
   Diabetes mellitus
   Depression and dementia
   Previous stroke
   Pneumonia and COPD
   Cancer
   Others
  
29
10
14
12
  6
  2
  6
  
55
25
18
15
12
  4
12
0.325
SD, standard deviation; COPD, chronic obstructive pulmonary disease.Kim S-R, et al.  •  Orthopedic Surgeon’s Awareness on Osteoporosis
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(7/67). Age (P = 0.384), comorbidity (P = 0.325), and operation 
(P = 0.277) in osteoporosis treatment group was not different 
with nonosteoporosis treatment group. However, gender (P =  
0.015) and diagnosis (P = 0.008) in osteoporosis treatment group 
was significant with nonosteoporosis treatment group (Table 3). 
  One hundred thirty-seven patients completed the face-to-face 
questionnaire-based interview. These included 56 patients who 
received osteoporosis medication and 81 patients who did not. 
Of these 137 patients, 82 (59.9%) were not informed of their diag-
nosis of osteoporosis by their surgeons and 49 (35.8%) were ac-
knowledged having DXA examination during hospital admis-
sion. Forty (71.4%) of the 56 patients who received osteoporosis 
medication were aware of their diagnoses. Because of the 56 (69%) 
of the 81 patients with osteoporosis did not receive osteoporo-
sis medication following reasons: 47 (84%) thought that treat-
ment was unnecessary, four had economic reasons, four had a 
transportation problem, and one had a medical insurance prob-
lem (Table 4).
DISCUSSION
Treatment of osteoporosis after hip fracture is important to pre-
vent secondary fracture and to decrease mortality rate. However, 
many studies have reported low rates of osteoporosis treatment 
after hip fracture. Improvement of the awareness of orthopedic 
surgeons concerning the importance of identifying patients with 
osteoporosis has shown definite benefit to overcome this issue 
(25). This prospective intervention study was performed to de-
termine 1) whether an education program directed at orthope-
dic surgeons could increase the osteoporosis treatment rate af-
ter a hip fracture, 2) whether the difference of mortality between 
osteoporosis management group and none management group, 
and 3) the patient barriers to osteoporosis management after a 
hip fracture. 
  Our observations suggest the rate of detection and treatment 
of osteoporosis after a hip fracture among patients treated in 
2007 was more than twofold greater than that in 2005. We used 
a simple, yet effective and easily applied intervention method 
in this study. Our study also highlights the importance of the or-
thopedic surgeon’s role as a first-line healthcare provider for pa-
tients with osteoporosis who have a fracture, because these pa-
tients regularly attend scheduled visits for radiologic and clini-
cal evaluations after surgery. Interventions targeting clinicians 
with a view toward increasing treatment rates have been studied 
(22, 26, 27) (Table 2). Comparative studies conducted on ortho-
pedic surgeon and physician-based interventions for improving 
osteoporosis management after hip fracture show awareness of 
orthopedic surgeon has a greater effect on osteoporosis manage-
ment rates after hip fracture (20, 23). In particular, Miki et al. (22) 
reported the effects of osteoporosis management initiated by an 
orthopedic team and by primary care physicians (22). The osteo-
porosis treatment rate 6 months after hip fracture was higher 
for the orthopedic team (58%) than for the primary care physi-
cians (29%) (22). Our study also showed an improved medica-
tion rate of osteoporosis from 15% to 32%. However, the osteo-
porosis treatment rate 6 months after hip fracture was still lower 
than those reported in other intervention studies (22, 23, 27). In 
addition, even after the educational program, the physician’s 
detection rate and treatment rate of osteoporosis did not increase 
in seven (32%) out of the 22 orthopedic surgeons, who partici-
pated in this study. More effective educational campaign and 
reminiscence of osteoporosis treatment are warranted. This may 
have been attributable to the high mortality rate (10.6%) within 
the first 6 months and the high lost-to-follow-up rate (40%) in 
our study. However, of the 129 patients who were followed for 
more than 6 months, 32.6% (42/129) remained on osteoporosis 
medication. The other possible reason concerns differences be-
tween intervention modalities. In the current study, orthopedic 
surgeons only underwent education sessions, whereas previous 
studies have involved multimodal approaches, including nurse 
management programs, standardized algorithms, and monitor-
ing of adherence to treatment (20, 22, 23). Finally, the propor-
Table 4. Survey questionnaire and response rates
Question                Response
Number (%) of  
patients with  
medication (n = 56)
Number (%)  
of patients without  
medication (n = 81)
Number (%)  
of questionnaires  
(n = 137)
Have you heard the diagnosis 
   of osteoporosis from your doctor?
Yes
No
26 (46.4)
30 (53.6)
   29 (35.8)
   52 (64.2)
   55 (40.1)
   82 (59.9)
Was bone mineral density examined 
   at the hospital?
Yes
No
25 (44.6)
27 (48.2)
   24 (29.6)
   50 (61.7)
   49 (35.8)
   77 (56.2)
Have you received an antiosteoporosis 
   drug?
Yes
No
40 (71.4)
16 (28.6)
0
   73 (90.1)
   40 (29.2)
89 (65)
Why do not you start osteoporosis 
   treatment?
Do not think it is a necessity  
   to treat osteoporosis
Economic reason(s)
Transportation  problem(s)
Medical insurance problem(s)
Other(s)
0
0
0
0
0
47 (58)
   4 (4.9)
   4 (4.9)
   1 (1.2)
   14 (17.3)
   47 (34.3)
   4 (2.9)
   4 (2.9)
   1 (0.7)
   14 (10.2)Kim S-R, et al.  •  Orthopaedic Surgeon’s Awareness on Osteoporosis
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tion of patients in whom antiresorptive therapy is contraindicat-
ed also could have affected results (28). This shows that improv-
ing the awareness of orthopedic surgeons concerning the impor-
tance of identifying patients with osteoporosis is beneficial (25). 
Two intervention studies after hip fracture have reported im-
proved osteoporosis treatment rates (17, 23). Intervention meth-
ods can be classified as a nationwide medical system, patient 
education, and doctor awareness. Patient education programs 
or systemic approaches generally are considered more effective. 
However, doctor’s awareness should be changed before perform-
ing studies of education programs or systemic changes for pa-
tients.
  A high mortality rate, low follow-up rate, and the presence of 
life threatening comorbidities add to the difficulties of commenc-
ing osteoporosis treatment after a hip fracture in the elderly. 
However, the mortality rate of patients with osteoporosis medi-
cation in our study was lower at final follow-up than that of os-
teoporosis patients who did not receive medication. The ran-
domized controlled intervention trial by Lyles et al. (16) showed 
that intravenous bisphosphonate reduces fracture rates and mor-
tality. Our study also showed that these are benefits of osteopo-
rosis medication after hip fracture. However, we could not eval-
uate reduction of recurrent fracture rate after osteoporosis med-
ication because of high patient mortality, relatively small cohort 
size, and short follow-up duration. Nevertheless, other interven-
tion studies have shown that osteoporosis medication after hip 
fracture can reduce recurrent hip fracture rates (15, 16). 
  The results of the patient questionnaire showed that patient 
education is required to encourage osteoporosis treatment after 
a hip fracture, because most patients were not given enough ap-
propriate information by physicians or hospital staff either in 
the hospital or during follow-up. Furthermore, of the patients 
given osteoporosis medication, 23% could not recall their med-
ication history or the name of the medication administered. Pa-
tients who did not receive osteoporosis medication thought com-
monly that such medication was unnecessary. Bogoch et al. (17) 
described four categories of barriers to treatment, namely, those 
associated with patients, physicians, orthopedic surgeons, and 
medical care systems. However, Kaufman et al. (25) described 
10 different barriers to osteoporotic treatment after a hip frac-
ture. Both studies emphasized the importance of the orthope-
dic surgeon’s role in overcoming these barriers. 
  Several limitations of this study should be considered. First, 
the medical care system in Korea is unique compared to that in 
other countries. All Korean nationals are legally obliged to en-
roll in the Korean National Health Insurance Program. Patients 
pay an average of 30% of all medical costs to clinics or hospitals 
that manage them for almost all diseases, except for those not 
covered by insurance, such as cosmetic surgery or some new 
unproven therapies, for which the patients themselves pay 100% 
of the total costs. All clinics and hospitals then submit data on 
inpatients and outpatients, including data on diagnosis and med-
ical costs, to the Korean Health Insurance Review and Assess-
ment Service to reimburse 70% of the total medical cost. In Korea, 
patients with fractures are routinely followed by orthopedic sur-
geons because there is no such primary-care-physician system 
in which patients can register with a physician who would be 
accountable for their continuing care and referral. Therefore, 
osteoporosis treatment for patients with a fragility fracture sub-
stantially depends on the responsible orthopedic surgeon (29). 
The findings of intervention studies regarding the effectiveness 
of intervention programs provided by orthopedic surgeons and 
primary care physicians are less likely applicable to Korean med-
ical system (8, 22, 30). However, active participation of orthope-
dic surgeons in our study showed an increase of osteoporosis 
treatment after a hip fracture and improved outcome after that 
fracture. Second, this study was performed in various hospital 
settings in the same cohort, and two of the hospitals involved 
were not equipped with central DXA and referred their patients 
to another hospital for DXA study. Intervention studies that have 
investigated the treatment of osteoporosis after hip fracture in-
volved one or two specific centers, and it is difficult to extrapolate 
results from other university and local hospitals. Third, 25 pa-
tients were lost in follow-up. For these patients, we were able to 
confirm only mortality at the Korea National Statistical office. 
Furthermore, these patients’ osteoporosis medication histories 
could not be confirmed. Fourth, the interventional education 
program was not validated. However, it specifically targeted over-
coming barriers to osteoporosis detection, as described previ-
ously (9, 20, 23, 25). Fifth, we did not assess patient’s knowledge 
of osteoporosis prior to the intervention, which might have affect-
ed the rate of osteoporosis treatment after a hip fracture.
  The straightforward, systematic approach described for the 
education of orthopedic surgeons increased osteoporosis diag-
nosis and treatment rates. Despite more than twofold increase 
in osteoporosis detection, observed between 2005 and 2007, 
additional intervention studies are required to further improve-
ment of osteoporosis treatment rates after hip fracture.
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